Professional Documents
Culture Documents
January 5, 2010
Company also owns an industry leading Healthcare IT & services unit Both segments are benefiting from favorable demographic trends and have meaningful growth potential Intrinsic value of the business not currently reflected in the market
Significantly undervalued on a sum-ofthe-parts basis
2
ry a
nf us
ar o@ gm
ai l.c
om
Company Overview
MCK has over 175 years of operating history and is ranked #14 on the Forbes 500 list with over $100bn in revenues.
ry a
MCK also operates a technology segment which sells enterprise-software that helps customers including pharmacies, doctors and hospitals manage clinical data, revenue and inventory, automate processes, streamline communications and eliminate the need for paper prescriptions and medical records.
nf us
ar o@ gm
McKessons (MCK) primary business is drug distribution. MCK acts as the middleman delivering drugs from pharmaceutical companies to users such as pharmacies and hospitals.
ai l.c
om
ar o@ gm
ry a
Distributes pharmaceuticals and health and beauty products to retail pharmacies and institutional providers like hospitals and health systems
nf us
ai l.c
Provides software, automation, services and consulting to hospitals, physician offices, imaging centers, home health care agencies and payors
om
McKesson Technology Solutions (MTS) Strong market position in fragmented industry Stimulus spending and digitization of health records driving growth Sticky customer base and strong customer captivity due to high switching costs and niche target markets Products used by 50% of hospitals and 70% of those with over 200 beds High margin, high multiple business
At current levels, the market is not giving any credit to the value of MCKs Health Care IT (HCIT) unit despite it contributing 15-20% of MCKs net income. Analysts and investors tend to value MCK based on its consolidated earnings rather than valuing each of its two business separately, which leads to drastic mispricing. In order to realize and unlock the intrinsic value of the business, management should consider spinning off MCKs technology segment, MTS
5
ry a
Multiple secular tailwinds driving growth High barriers to entry and huge moat due to economies of scale and irreplicable network Recession resistant business Low regulatory exposure Limited inventory risk Low margin, low multiple business
nf us
ar o@ gm
ai l.c
om
ry a
nf us
ar o@ gm
ai l.c
om
ry a
nf us
ar o@ gm
ai l.c
om
7
Source: MCK Company Presentation
ry a
nf us
ar o@ gm
ai l.c
Given its ability to generate significant cash flow, MCK should continue to be able to conduct substantial share repurchases over time
om
MCK recently increased its buyback program by $1bn, raising the total authorized share repurchase amount to ~$1.53bn or roughly 8.5% of its current shares outstanding
8
Source: MCK Company Presentation
ry a
2009
nf us
ar o@ gm
2008
Return on Equity
ai l.c
2007
om
2006
9
Source: McKesson 10K
$8.00 $7.00 $6.00 $5.00 $4.00 $3.00 $2.00 $1.00 $$(1.00) FY 2005 FY 2006
ry a
nf us
FY 2007 FCFPS
ar o@ gm
FY 2008 EPS FY 2009
$9.00
ai l.c
om
MCKs depreciation and amortization expense typically exceeds capital expenditures, leading to FCF per share that far greater than GAAP EPS
FY 2010
10
Source: Bloomberg
ry a
nf us
2014
ar o@ gm
2017
ai l.c
om
MCK has over $2.5bn of cash(1), a modest net cash position, ample interest coverage (~11x) and a staggered debt maturity schedule
2019
2027
Source: McKesson 10K (1) cash adjusted to reflect 12/30 US Oncology acquisition
11
ry a
Whereas in the past the company operated as more of a reseller of drugs, MCK and other drug distributors have been moving to a fee-for-service (FFS) model under which it is paid by manufacturers to distribute their drugs in exchange for a fee.
nf us
ar o@ gm
ai l.c
om
12
ry a
nf us
Secular tailwinds
ar o@ gm
ai l.c
om
13
Massive amount of upcoming drug patent expirations, leading to a surge in the availability of generic drugs which carry higher profit margins Pharmaceutical consumption and utilization on the rise due to expansion of healthcare coverage and aging of baby boomers Government policy and stimulus programs to drive revenue growth in MCKs technology segment
ry a
nf us
ar o@ gm
ai l.c
om
MCKs two businesses should benefit from a number of secular tailwinds as well as increases in government spending
14
ry a
nf us
ar o@ gm
ai l.c
om
15
ry a
nf us
ar o@ gm
ai l.c
om
16
Source: Goldman Sachs
ry a
nf us
ar o@ gm
ai l.c
om
17
Source: US Census
18.20%
ar o@ gm
ai l.c
om
nf us
23.41%
22.42%
9.85%
ry a
23.59%
8.92%
26.80%
25.88%
18 to 24 years 45 to 64 years
18 to 24 years 45 to 64 years
18 to 24 years 45 to 64 years
18
Source: US Census
ry a
nf us
ar o@ gm
ai l.c
om
19
Source: US Census
ry a
nf us
ar o@ gm
ai l.c
om
which should give rise to an increase in pharmaceutical utilization and further drive growth for MCK
20
Source: SIG
MCKs IT segment is likely to be one of the main beneficiaries of this incremental stimulus spending
ry a
nf us
ar o@ gm
ai l.c
om
21
ry a
nf us
ar o@ gm
ai l.c
om
22
Market Cap (mm) Enterprise Value 2010E Sales P / 2010E EPS P / 2011E EPS P / 2012E EPS
ar o@ gm
McKesson
Cardinal Health
$13,568 $12,995
ai l.c
om
Amerisourcebergen
$9,523 $9,208 $78,536 15.81 14.12 12.72
Median
$11,421 $10,977 $88,405 16.11 14.48 13.11
ry a
nf us
23
Data based on 1/5/11 closing prices
Market Cap (mm) Enterprise Value 2010E Sales P / 2010E EPS P / 2011E EPS P / 2012E EPS
ar o@ gm
Cerner
Allscripts
ai l.c
om
Median
$2,044 $1,938 $332 32.88 27.69 22.38
ry a
nf us
37.16 27.69 22.85
24
Data based on 1/5/11 closing prices
Sum-Of-The-Parts Analysis
Operating Profit (1) Interest Expense (2) Pre-Tax Income Income Tax (3) Net Income Shares Outstanding (4) EPS Estimated P/E Multiple (5)
Distribution Solutions Technology Solutions Implied Value Per Share $1,864 147 $1,717 566.6
om ai l.c
Technology Solutions CY 2011 $355 28 $327 107.9 $219.1 232 $0.94 High* 14.84 29.9 High
$1,150.4 232
nf us
ar o@ gm
$4.96 Low 14.12 22.9 Low
Based on the implied value of the MDS segment, MCKs current stock price only reflects the value of its distribution business
Currently, the market is ascribing zero value to MCKs IT business. Said differently, at todays price levels you are buying MCKs high quality distribution business at an attractive price and effectively getting its high-margin, high multiple technology business for free
Refer to notes on final slide for assumptions used
ry a
25
Note: Current Weakness in MTS Segment Masks Potential For the first half of FY 2011, the MTS segment has seen a (temporary) decline in operating profits by ~64% due to increased investment, a one-time non-cash impairment charge and revenue recognition delays. Management expects a strong second half of FY11 for MTS as investment slows, certain development issues are resolved and implementation schedules come online Consequently, investors are being overly pessimistic about the health and profitability of the MTS segment, allowing for a more attractive entry point
ry a
nf us
ar o@ gm
ai l.c
om
26
Spin-off rationale
ry a
nf us
ar o@ gm
ai l.c
om
27
Spin-off Rationale
Cross-selling opportunities still exist but given the level of penetration MTS has achieved, they have grown less important
MCK can choose to spin out the majority of MTS while retaining a stub holding in the spun-off entity to continue to build and grow the business while still unlocking its value for shareholders
The two businesses have very different growth and margin profiles and thus deserve vastly different earnings multiples. As a result, in its current form, the market has a difficult time assigning fair value to MCK Give shareholders a choice whether to hold the low-margin distribution business , the high-margin IT business or both Highlight the intrinsic value of the business
As a standalone entity, MTS would become 2nd largest publicly traded HCIT company by market cap (1)
ry a
nf us
ar o@ gm
MTS products are already deeply penetrated and thus there are few if any remaining synergies between the two businesses
ai l.c
om
The MTS business is the byproduct of a merger between HBO & Co. and MCK in 1999 and its subsequent build-out both organically and through a series of acquisitions
28
(1) Based on peer multiples and estimated earnings
The Transaction Is Not Without Precedence In order to re-focus on its core distribution business, McKesson competitor Cardinal Health (CAH) spun off its non-core tech assets in August 2009 into a separate entity, CareFusion (CFN), on a 1:2 basis At the time, Cardinal Health retained a 19% equity stake in CareFusion CareFusion is comprised of what was formerly Cardinal Healths high-margin, high growth clinical and medical products businesses
When taking into account the CareFusion shares received as a result of the spin-off and the appreciation of both Cardinal Health and CareFusion since the spin-off, investors that owned CAH as of the record date of August 25th, 2009 have earned a return of 49.5% versus a return on the S&P 500 of 24% over the same period
ry a
nf us
ar o@ gm
ai l.c
om
29
ry a
nf us
ar o@ gm
Risk factors
ai l.c
om
30
Risks
Disintermediation
ry a
nf us
Distribution business models are efficient and make economic sense Distributors in all industries allow their respective clients to focus on their own core competencies MCK and other drug distributors are akin to off-balance sheet financing and help businesses keep their cost structure down
ar o@ gm
ai l.c
om
31
ry a
nf us
ar o@ gm
Conclusion
ai l.c
om
32
Conclusion High quality business with strong competitive position, recurring revenue streams and multiple secular tailwinds Attractive valuation on a consolidated basis Trading at a significant discount to fair value on a sum-of-theparts basis Spin-off opportunity presents catalyst to realize value
Shares do not currently reflect value of highly profitable IT segment
ry a
nf us
ar o@ gm
ai l.c
om
33
Assumptions used
CY2011 operating profit is based on consensus estimates and allocates 84% to the MDS segment and 16% to the MTS segment based on historical precedent Interest expense is computed based on historical interest cost and is allocated 84% to the MDS segment and 16% to the MTS segment; conservative estimate as MCK has been paying down debt The tax rate is assumed to be 33% based on historical precedent and management guidance Share outstanding is based on the assumption that the full $1.53bn share buyback program is exercised, resulting in a share count reduction of 21mm shares Earnings multiples are for CY11 are based on those of the comparables listed in the peer slides, with the exception of Athenahealth which was excluded as an outlier
ry a
nf us
ar o@ gm
ai l.c
om
34